Focal
Immunovant Refines R&D Strategy with New Leadership
Immunovant, Roivant, R&D Focus, Leadership Changes, IMVT-1402
Novartis Reports Strong Financial Performance in 2024, Validating Pure-Play Strategy
Novartis, earnings, pure-play strategy, pharmaceutical industry, financial performance, R&D focus, core therapeutic areas